LeMaitre Vascular, Inc. (Nasdaq:LMAT), a provider of peripheral
vascular devices and implants, today announced Q1 2010 financial
results. The Company posted record quarterly sales of $13.8 million
and operating income of $1.3 million. The Company also updated its
sales and operating income guidance.
Q1 2010 sales increased 22% versus Q1 2009, with Vascular up 28%
and Endovascular up 12%. Vascular sales benefited from a larger
sales force in the Americas, growth across all product lines and
the stronger Euro. Geographically, sales in the Americas increased
20%, while sales in Europe and Japan grew 23% and 34%,
respectively. In Q1 2010, 93% of the Company's sales were
direct-to-hospital. On an organic basis, Q1 2010 sales increased
18% versus the year earlier period.
The Company reported a gross margin of 74.7% in Q1 2010, up from
72.8% in Q1 2009. The increase was driven by manufacturing
efficiencies and higher average selling prices.
Q1 2010 operating profit was $1.3 million versus a Q1 2009
operating loss of $1.6 million. Sales growth and the expanded
gross margin drove this bottom-line improvement, partially offset
by increased operating expenses. Also, the Company incurred $1.8
million of restructuring charges in Q1 2009 related to a
distributor buyout.
Net income in Q1 2010 was $1.0 million, or $0.06 per diluted
share, versus a net loss of $1.9 million in Q1 2009, or ($0.12) per
diluted share.
George W. LeMaitre, Chairman and CEO said, "Robust 22% sales
growth and an improved gross margin produced solid bottom-line
results in Q1. This was our fourth straight quarter of $1+ million
operating income. Our open vascular category and our enlarged
domestic sales force drove sales growth in Q1 2010. We also
experienced rapid growth in our newer international direct markets
such as France, UK and Japan. In addition, our stepped-up
regulatory efforts produced six approvals since the beginning of
the year, including two U.S. 510(k)s."
The Company's cash and marketable securities increased by
$98,000 during Q1 to $24.1 million at March 31, 2010. This was the
result of $1.0 million in net income and $562,000 of depreciation,
amortization and stock-based compensation, largely offset by
$982,000 in annual bonus payments, and $315,000 of share
repurchases.
Sales and marketing expenses increased 18% in Q1 2010 to $4.9
million, representing 35% of sales versus 37% in the year earlier
quarter. The spending increase was driven mainly by the
larger direct sales force as well as increased commissions. The
Company ended Q1 2010 with 61 sales reps versus 52 at the end of Q1
2009.
General and administrative expenses increased 4% in Q1 2010 to
$2.6 million, representing 19% of sales versus 22% in the
year-earlier quarter.
R&D expenses increased 17% to $1.5 million in Q1 2010,
representing 11% of sales versus 12% in the year-earlier quarter.
To date the Company has received 6 regulatory approvals in
2010: the AlboGraft vascular graft and AnastoClip GC in the
United States, the TAArget Thoracic Stent Graft and The UnBalloon
in Russia as well as two CE Marks in Europe.
Business Outlook
Despite the recent sequential weakness in the Euro, the Company
continues to expect 2010 sales of $55.0 million, and is increasing
its 2010 operating income guidance from $4.5 million to $5.0
million. Our annual sales guidance implies 10% organic growth
versus 2009. The Company expects Q2 2010 sales of $13.7
million and operating income of $1.1 million. Our quarterly sales
guidance implies 10% organic growth versus Q2 2009. Guidance
amounts exclude the effects of future acquisitions, operational
restructurings, foreign exchange rate fluctuations, and distributor
terminations.
Conference Call Reminder
Management will conduct a conference call at 5:00 p.m. EDT today
to review the Company's financial results and discuss its business
outlook for the remainder of the year. The conference call
will be broadcast live over the Internet. Individuals who are
interested in listening to the webcast should log on to the
Company's website at www.lemaitre.com/investor. The conference
call may also be accessed by dialing 800-291-5365 (+1-617-614-3922
for international callers), using passcode 37954911. For
individuals unable to join the live conference call, a replay will
be available on the Company's website.
About LeMaitre Vascular
LeMaitre Vascular is a provider of devices for the treatment of
peripheral vascular disease. The Company develops,
manufactures and markets disposable and implantable vascular
devices to address the needs of vascular surgeons. The Company's
devices are used to treat peripheral vascular disease; a condition
the Company believes affects at least 20 million people
worldwide.
Well-known to vascular surgeons, the Company's diversified
product portfolio consists of brand name devices used in arteries
and veins outside of the heart, including the Expandable LeMaitre
Valvulotome, Pruitt F3 Carotid Shunt, TAArget Thoracic Stent Graft,
The UnBalloon Non-Occlusive Modeling Catheter and AlboGraft
Vascular Graft.
LeMaitre and the LeMaitre Vascular logo are registered
trademarks of LeMaitre Vascular, Inc. This press release
contains other trademarks and trade names of the Company and third
parties.
For more information about the Company, please visit
http://www.lemaitre.com.
Use of Non-GAAP Financial Measures
LeMaitre Vascular management believes that in order to properly
understand the Company's short-term and long-term financial trends,
investors may wish to consider the impact of certain non-cash or
non-recurring items, when used as a supplement to financial
performance measures in accordance with GAAP. These items result
from facts and circumstances that vary in frequency and/or impact
on continuing operations. In addition, management uses results of
operations before such items to evaluate the operational
performance of the Company and as a basis for strategic planning.
Investors should consider these non-GAAP measures in addition to,
and not as a substitute for, financial performance measures in
accordance with GAAP. In addition to the description provided
below, reconciliation of GAAP to non-GAAP results is provided in
the financial statement tables included in this press release.
This press release includes sales growth after adjusting for
foreign exchange and distribution of the XenoSure Biologic Patch.
We refer to this as "organic" sales growth. The Company
analyzes net sales on a constant currency basis net of acquisitions
and other non-recurring events to better measure the comparability
of results between periods. Because changes in foreign currency
exchange rates have a non-operating impact on net sales, and
acquisitions and other strategic transactions are episodic in
nature and highly variable in sales impact, the Company believes
that evaluating growth in sales on a constant currency basis net of
such transactions provides an additional and meaningful assessment
of sales to both management and the Company's investors. The
Company commenced distribution of the XenoSure Biologic Patch on
January 26, 2009.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Statements in this press release regarding the Company's
business that are not historical facts may be "forward-looking
statements" that involve risks and
uncertainties. Specifically, statements regarding the
Company's financial and operational guidance are forward-looking,
involving risks and uncertainties. The Company's current
quarterly financial results, as discussed in this release, are
preliminary and unaudited, and subject to
adjustment. Forward-looking statements are based on
management's current, preliminary expectations and are subject to
risks and uncertainties that could cause actual results to differ
from the results predicted. These risks and uncertainties
include, but are not limited to, the risk that the Company does not
generate sufficient operating scale to maintain or increase
profitability; risks related to product demand and market
acceptance of the Company's products; the possibility that the
Company's new products may fail to provide the desired safety and
efficacy or may not be accepted by the market for other reasons;
the significant competition the Company faces from other companies,
technologies, and alternative medical procedures; the risk that the
Company may fail to expand its product offerings through internal
development or acquisition; the general uncertainty related to
seeking regulatory approvals for the Company's products; and other
risks and uncertainties included under the heading "Risk Factors"
in our most recent Annual Report on Form 10-K, as updated by our
subsequent filings with the SEC, all of which are available on the
Company's investor relations website at http://www.lemaitre.com and
on the SEC's website at http://www.sec.gov. Undue reliance
should not be placed on forward-looking statements, which speak
only as of the date they are made. The Company undertakes no
obligation to update publicly any forward-looking statements to
reflect new information, events, or circumstances after the date
they were made, or to reflect the occurrence of unanticipated
events.
Financial Statements
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands)
|
|
|
|
|
March 31, 2010
|
December 31, 2009
|
|
(unaudited)
|
|
Assets
|
|
|
|
|
|
Current assets:
|
|
|
Cash and cash equivalents
|
$ 23,662
|
$ 23,192
|
Marketable securities
|
436
|
808
|
Accounts receivable, net
|
8,054
|
7,778
|
Inventories
|
6,252
|
6,498
|
Other current assets
|
1,434
|
1,274
|
|
|
|
Total current assets
|
39,838
|
39,550
|
|
|
|
Property and equipment, net
|
2,144
|
2,101
|
Goodwill
|
11,022
|
11,022
|
Other intangibles, net
|
3,105
|
3,316
|
Other assets
|
842
|
917
|
|
|
|
Total assets
|
$ 56,951
|
$ 56,906
|
|
|
|
|
|
|
Liabilities and stockholders' equity
|
|
|
|
|
|
Current liabilities:
|
|
|
Accounts payable
|
$ 1,483
|
$ 1,136
|
Accrued expenses
|
4,749
|
5,412
|
Total current liabilities
|
6,232
|
6,548
|
|
|
|
Long term debt
|
149
|
188
|
Deferred tax liabilities
|
1,616
|
1,546
|
Other long-term liabilities
|
376
|
411
|
Total liabilities
|
8,373
|
8,693
|
|
|
|
Stockholders' equity
|
|
|
Common stock
|
159
|
159
|
Additional paid-in capital
|
63,690
|
63,475
|
Accumulated deficit
|
(13,575)
|
(14,596)
|
Accumulated other comprehensive income (loss)
|
(457)
|
94
|
Less: treasury stock
|
(1,239)
|
(919)
|
Total stockholders' equity
|
48,578
|
48,213
|
|
|
|
Total liabilities and stockholders' equity
|
$ 56,951
|
$ 56,906
|
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS
(amounts in thousands, except per share amounts)
(unaudited)
|
|
|
|
|
For the three months ended
|
|
March 31, 2010
|
March 31, 2009
|
|
|
|
Net sales
|
$ 13,815
|
$ 11,348
|
Cost of sales
|
3,497
|
3,082
|
|
|
|
Gross profit
|
10,318
|
8,266
|
|
|
|
Operating expenses:
|
|
|
Sales and marketing
|
4,894
|
4,146
|
General and administrative
|
2,614
|
2,525
|
Research and development
|
1,540
|
1,311
|
Restructuring charges
|
--
|
1,777
|
Impairment charge
|
--
|
73
|
|
|
|
Total operating expenses
|
9,048
|
9,832
|
|
|
|
Income (loss) from operations
|
1,270
|
(1,566)
|
|
|
|
Other income:
|
|
|
Interest income (expense), net
|
3
|
(22)
|
Other income (loss), net
|
26
|
(86)
|
|
|
|
Total other income (loss), net
|
29
|
(108)
|
|
|
|
Income (loss) before income taxes
|
1,299
|
(1,674)
|
|
|
|
Provision for income taxes
|
278
|
207
|
|
|
|
Net income (loss)
|
$ 1,021
|
$ (1,881)
|
|
|
|
Net income (loss) per share of common stock:
|
|
|
Basic
|
$ 0.07
|
$ (0.12)
|
Diluted
|
$ 0.06
|
$ (0.12)
|
|
|
|
Weighted average shares outstanding:
|
|
|
Basic
|
15,678
|
15,661
|
Diluted
|
16,036
|
15,661
|
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
SELECTED NET SALES INFORMATION
(amounts in thousands)
(unaudited)
|
|
|
|
|
|
|
For the three months ended
|
|
March 31, 2010
|
March 31, 2009
|
|
$
|
%
|
$
|
%
|
Net Sales by Product
Category:
|
|
|
|
|
Vascular
|
$ 9,557
|
69%
|
$ 7,484
|
66%
|
Endovascular
|
3,292
|
24%
|
2,932
|
26%
|
General Surgery
|
955
|
7%
|
880
|
8%
|
|
13,804
|
100%
|
11,296
|
100%
|
OEM
|
11
|
0%
|
52
|
0%
|
Total Net Sales
|
$ 13,815
|
100%
|
$ 11,348
|
100%
|
|
|
|
|
|
|
|
|
|
|
Net Sales by Geography
|
|
|
|
|
Americas
|
$ 8,048
|
58%
|
$ 6,681
|
59%
|
International
|
5,767
|
42%
|
4,667
|
41%
|
Total Net Sales
|
$ 13,815
|
100%
|
$ 11,348
|
100%
|
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
IMPACT OF FOREIGN CURRENCY AND BUSINESS
ACTIVITIES
(amounts in thousands)
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
2010
|
2009
|
2008
|
|
Q1
|
Q4
|
Q3
|
Q2
|
Q1
|
Q4
|
Q3
|
Q2
|
Q1
|
|
|
|
|
|
|
|
|
|
|
Total net sales
|
13,815
|
13,584
|
13,346
|
12,630
|
11,348
|
12,111
|
12,023
|
12,739
|
11,847
|
Impact of currency exchange rate fluctuations (1)
|
314
|
613
|
(215)
|
(699)
|
(622)
|
(448)
|
452
|
836
|
674
|
Net impact of acquisitions, distributed sales
and discontinued products, excluding currency exchange rate
fluctuations (2)
|
95
|
397
|
333
|
234
|
101
|
235
|
703
|
929
|
1,133
|
|
|
|
|
|
|
|
|
|
|
(1) Represents the impact of the change in foreign exchange
rates compared to the corresponding quarter of the prior year based
on the weighted averge rate for each quarter.exchange
|
(2) Represents the impact of sales of products of acquired
businesses and distributed sales of other manufacturers' products,
net of sales related to discontinued products and other activities,
based on 12 months' sales following the date of the event or
transaction, for the current period only.
|
|
|
|
|
LEMAITRE VASCULAR, INC (NASDAQ: LMAT)
NON-GAAP FINANCIAL MEASURES
(amounts in thousands)
(unaudited)
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP sales growth:
|
|
|
|
For the three months ending March 31, 2010
|
|
|
|
Net sales as reported
|
$13,815
|
|
|
Impact of currency exchange rate fluctuations
|
(314)
|
|
|
Net impact of acquisitions, distributed sales and
discontinued
products, excluding currency
|
(95)
|
|
|
Adjusted net sales
|
|
$13,406
|
|
|
|
|
|
For the three months ending March 31, 2009
|
|
|
|
Net Sales as reported
|
|
$11,348
|
|
|
|
|
|
Adjusted net sales increase for the three months ending
March 31, 2010
|
|
$ 2,058
|
18%
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP sales growth
for the Americas:
|
|
|
|
For the three months ending March 31, 2010
|
|
|
|
Net sales as reported
|
$ 8,048
|
|
|
Net impact of acquisitions, distributed sales and
discontinued products, excluding currency
|
(95)
|
|
|
Adjusted net sales
|
|
$ 7,953
|
|
|
|
|
|
For the three months ending March 31, 2009
|
|
|
|
Net Sales as reported
|
|
$ 6,681
|
|
|
|
|
|
Adjusted net sales increase for the three months ending
March 31, 2010
|
|
$ 1,272
|
19%
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP sales growth
for International:
|
|
|
|
For the three months ending March 31, 2010
|
|
|
|
Net sales as reported
|
$ 5,767
|
|
|
Impact of currency exchange rate fluctuations
|
(314)
|
|
|
Adjusted net sales
|
|
$ 5,453
|
|
|
|
|
|
For the three months ending March 31, 2009
|
|
|
|
Net Sales as reported
|
|
$ 4,667
|
|
|
|
|
|
Adjusted net sales increase for the three months ending
March 31, 2010
|
|
$ 786
|
17%
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP sales growth for
Quarterly Guidance:
|
|
|
|
For the three months ending June 30, 2010
|
|
|
|
Net sales per guidance
|
$13,700
|
|
|
|
|
|
|
Net impact of acquisitions, distributed sales and
discontinued
products, excluding currency
|
38
|
|
|
Impact of currency exchange rate fluctuations
|
131
|
|
|
Adjusted net sales
|
|
$13,869
|
|
|
|
|
|
For the three months ending June 30, 2009
|
|
|
|
Net Sales as reported
|
|
$12,632
|
|
|
|
|
|
Adjusted net sales increase for the three months
ending
June 30, 2010
|
|
$ 1,237
|
10%
|
|
|
|
|
|
|
|
|
Reconciliation between GAAP and Non-GAAP sales growth for
Annual Guidance:
|
|
|
|
For the year ending December 31, 2010
|
|
|
|
Net sales per guidance
|
$55,000
|
|
|
Net impact of acquisitions, distributed sales and
discontinued
products, excluding currency
|
$ 49
|
|
|
Impact of currency exchange rate fluctuations
|
846
|
|
|
Adjusted net sales
|
|
$55,895
|
|
|
|
|
|
For the year ending December 31, 2009
|
|
|
|
Net Sales as reported
|
|
$50,908
|
|
|
|
|
|
Adjusted net sales increase for the year ending December
31, 2010
|
|
$ 4,987
|
10%
|
CONTACT: LeMaitre Vascular Inc.
J.J. Pellegrino, Chief Financial Officer
781.221.2266 x106
jpellegrino@lemaitre.com
![](http://www.globenewswire.com/newsroom/ti?nf=MTYwIzE5MDI3NSMxMDUwNw==)
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From May 2024 to Jun 2024
LeMaitre Vascular (NASDAQ:LMAT)
Historical Stock Chart
From Jun 2023 to Jun 2024